{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:37:44Z","timestamp":1790912264981,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.pep.2024.106477","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:24:33Z","timestamp":1711185873000},"page":"106477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression"],"prefix":"10.1016","volume":"219","author":[{"given":"Dezheng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2024.106477_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/dmrr.2501","article-title":"Incretins: their physiology and application in the treatment of diabetes mellitus","volume":"30","author":"Tasyurek","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.pep.2024.106477_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.pep.2024.106477_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.pep.2024.106477_bib4","first-page":"178","article-title":"Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes","volume":"10","author":"Tran","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.pep.2024.106477_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.pep.2024.106477_bib6","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.pep.2024.106477_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1573399815666190502114924","article-title":"GLP-1 receptor agonists in type 2 diabetes mellitus","volume":"16","author":"Dahiya","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.pep.2024.106477_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcjd.2017.08.242","article-title":"Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes","volume":"41","author":"Lovshin","year":"2017","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.pep.2024.106477_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jcjd.2018.05.008","article-title":"Semaglutide: review and place in therapy for adults with type 2 diabetes","volume":"43","author":"Goldenberg","year":"2019","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.pep.2024.106477_bib10","first-page":"488","article-title":"[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic\u00ae)]","volume":"74","author":"Scheen","year":"2019","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.pep.2024.106477_bib11","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pep.2024.106477_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pep.2024.106477_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pep.2024.106477_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pep.2024.106477_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pep.2024.106477_bib16","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pep.2024.106477_bib17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pep.2024.106477_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pep.2024.106477_bib19","series-title":"Semi-recombinant Preparation of GLP-1 Analogues United States, 20100317057, NOVO NORDISK A\/S (BEGSVAEND, DK)","author":"Lau","year":"2010"},{"key":"10.1016\/j.pep.2024.106477_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acscombsci.0c00134","article-title":"Total synthesis of semaglutide based on a soluble hydrophobic-support-assisted liquid-phase synthetic method","volume":"22","author":"Liu","year":"2020","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.pep.2024.106477_bib21","doi-asserted-by":"crossref","first-page":"e3407","DOI":"10.1002\/psc.3407","article-title":"Efficient synthesis of Aib(8) -Arg(34) -GLP-1 (7-37) by liquid-phase fragment condensation","volume":"28","author":"Zhang","year":"2022","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.pep.2024.106477_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3452","article-title":"Hectogram-scale synthesis of [Aib(8) , Arg(34) ]-GLP-1 (7-37) by liquid-phase fragment condensation","volume":"29","author":"Zhang","year":"2023","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.pep.2024.106477_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/0929866527999200729182831","article-title":"Expression, solubilization, refolding and final purification of recombinant proteins as expressed in the form of \"classical inclusion bodies\" in E. coli","volume":"28","author":"Hashemzadeh","year":"2021","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.pep.2024.106477_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.febslet.2013.09.028","article-title":"Targeted expression, purification, and cleavage of fusion proteins from inclusion bodies in Escherichia coli","volume":"588","author":"Hwang","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pep.2024.106477_bib25","first-page":"399","article-title":"[Solid-phase chemical synthesis and oxidative refolding of Hainantoxin-III]","volume":"25","author":"Pi","year":"2007","journal-title":"Se Pu"}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592824000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592824000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T20:08:08Z","timestamp":1714853288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592824000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"alternative-id":["S1046592824000494"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2024.106477","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2024.106477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106477"}}